(KALV) Kalvista Pharmaceuticals - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4834971032

Stock: Drug Therapies, Small Molecules, Inhibitors, Disease Treatment

Total Rating 39
Risk 26
Buy Signal 1.40
Biotechnology +8.1
Biotechnology +6.7
Market Cap: 820m
Avg Trading Vol: 10.6M USD
ATR: 4.89%
Peers RS (IBD): 34.3
Risk 5d forecast
Volatility 60.9%
Relative Tail Risk -7.38%
Reward TTM
Sharpe Ratio 0.84
Alpha 35.57
Character TTM
Beta 0.301
Beta Downside 1.213
Drawdowns 3y
Max DD 53.87%
CAGR/Max DD 0.60

EPS (Earnings per Share)

EPS (Earnings per Share) of KALV over the last years for every Quarter: "2021-01": -0.56, "2021-04": -0.65, "2021-07": -0.66, "2021-10": -0.8, "2022-01": -0.92, "2022-04": -0.98, "2022-07": -0.94, "2022-10": -0.9, "2023-01": -0.75, "2023-04": -0.77, "2023-07": -0.74, "2023-10": -0.8, "2024-01": -0.84, "2024-04": -1.02, "2024-07": -0.87, "2024-10": -0.91, "2025-01": -0.92, "2025-04": -0.99, "2025-07": -1.12, "2025-10": -0.92,
EPS CAGR: 0.00%
EPS Trend: -33.8%
Last SUE: 0.34
Qual. Beats: 0

Revenue

Revenue of KALV over the last years for every Quarter: 2021-01: 0, 2021-04: 12.69, 2021-07: 33.579, 2021-10: 0, 2022-01: 0, 2022-04: 0, 2022-07: 0, 2022-10: 0, 2023-01: 0, 2023-04: 0, 2023-07: 0, 2023-10: 0, 2024-01: 0, 2024-04: 1.206, 2024-07: 0, 2024-10: 0, 2025-01: 0, 2025-04: 0, 2025-07: 1.426, 2025-10: 13.692,
Rev. CAGR: 89.54%
Rev. Trend: 54.3%
Last SUE: 4.00
Qual. Beats: 1

Description: KALV Kalvista Pharmaceuticals March 04, 2026

KalVista Pharmaceuticals, Inc. (KALV) is a biopharmaceutical company focused on developing drug therapies, specifically kallikrein inhibitors, for diseases with unmet needs. The companys primary focus is on Hereditary Angioedema (HAE), a rare genetic disorder.

KALVs lead product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor. They are also developing an oral Factor XIIa inhibitor for HAE, currently in preclinical trials. The company is developing various oral formulations, including those for pediatric and adult HAE patients.

The biotechnology sector is characterized by extensive research and development cycles and high regulatory hurdles. KalVistas business model centers on developing and commercializing specialized treatments for rare diseases, a common strategy within the biopharmaceutical industry.

To further understand KalVistas market position and financial health, consider exploring its detailed financials on ValueRay.

Headlines to watch out for

  • EKTERLY commercialization success drives revenue growth
  • Regulatory approval for HAE treatments impacts stock
  • Clinical trial outcomes for Factor XIIa influence valuation
  • Competition in HAE market affects market share
  • Pediatric HAE formulation development expands addressable market

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: -210.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.47 > 0.02 and ΔFCF/TA 29.20 > 1.0
NWC/Revenue: 1853 % < 20% (prev 10.8k%; Δ -8935 % < -1%)
CFO/TA -0.47 > 3% & CFO -160.2m > Net Income -210.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 7.22 > 1.5 & < 3
Outstanding Shares: last quarter (53.9m) vs 12m ago 15.39% < -2%
Gross Margin: -17.16% > 18% (prev -20.29%; Δ 312.8% > 0.5%)
Asset Turnover: 6.04% > 50% (prev 0.75%; Δ 5.29% > 0%)
Interest Coverage Ratio: -13.75 > 6 (EBITDA TTM -192.3m / Interest Expense TTM 14.1m)

Altman Z'' -9.30

A: 0.82 (Total Current Assets 325.2m - Total Current Liabilities 45.1m) / Total Assets 339.9m
B: -2.17 (Retained Earnings -739.1m / Total Assets 339.9m)
C: -0.77 (EBIT TTM -193.4m / Avg Total Assets 250.4m)
D: -2.31 (Book Value of Equity -745.8m / Total Liabilities 322.9m)
Altman-Z'' Score: -9.30 = D

Beneish M 1.00

DSRI: 0.05 (Receivables 7.12m/10.9m, Revenue 15.1m/1.21m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.73 (AQ_t 0.01 / AQ_t-1 0.00)
SGI: 12.54 (Revenue 15.1m / 1.21m)
TATA: -0.15 (NI -210.3m - CFO -160.2m) / TA 339.9m)
Beneish M-Score: 4.75 (Cap -4..+1) = D

What is the price of KALV shares?

As of March 10, 2026, the stock is trading at USD 17.30 with a total of 2,017,156 shares traded.
Over the past week, the price has changed by +7.72%, over one month by +17.13%, over three months by +7.05% and over the past year by +44.29%.

Is KALV a buy, sell or hold?

Kalvista Pharmaceuticals has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy KALV.
  • StrongBuy: 7
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the KALV price?

Issuer Target Up/Down from current
Wallstreet Target Price 34 96.5%
Analysts Target Price 34 96.5%

KALV Fundamental Data Overview March 08, 2026

P/E Forward = 19.7628
P/S = 575.2919
P/B = 48.2002
Revenue TTM = 15.1m USD
EBIT TTM = -193.4m USD
EBITDA TTM = -192.3m USD
Long Term Debt = 139.0m USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.43m USD (from shortTermDebt, last quarter)
Debt = 149.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -93.9m USD (from netDebt column, last quarter)
Enterprise Value = 660.8m USD (820.4m + Debt 149.6m - CCE 309.2m)
Interest Coverage Ratio = -13.75 (Ebit TTM -193.4m / Interest Expense TTM 14.1m)
EV/FCF = -4.12x (Enterprise Value 660.8m / FCF TTM -160.3m)
FCF Yield = -24.26% (FCF TTM -160.3m / Enterprise Value 660.8m)
FCF Margin = -1060 % (FCF TTM -160.3m / Revenue TTM 15.1m)
Net Margin = -1391 % (Net Income TTM -210.3m / Revenue TTM 15.1m)
Gross Margin = -17.16% ((Revenue TTM 15.1m - Cost of Revenue TTM 17.7m) / Revenue TTM)
Gross Margin QoQ = 91.00% (prev 58.63%)
Tobins Q-Ratio = 1.94 (Enterprise Value 660.8m / Total Assets 339.9m)
Interest Expense / Debt = 3.18% (Interest Expense 4.76m / Debt 149.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -152.8m (EBIT -193.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.22 (Total Current Assets 325.2m / Total Current Liabilities 45.1m)
Debt / Equity = 8.80 (Debt 149.6m / totalStockholderEquity, last quarter 17.0m)
Debt / EBITDA = 0.49 (negative EBITDA) (Net Debt -93.9m / EBITDA -192.3m)
Debt / FCF = 0.59 (negative FCF - burning cash) (Net Debt -93.9m / FCF TTM -160.3m)
Total Stockholder Equity = 74.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -84.00% (Net Income -210.3m / Total Assets 339.9m)
RoE = -282.0% (Net Income TTM -210.3m / Total Stockholder Equity 74.6m)
RoCE = -90.56% (EBIT -193.4m / Capital Employed (Equity 74.6m + L.T.Debt 139.0m))
RoIC = -163.0% (out of range, set to none) (NOPAT -152.8m / Invested Capital 93.8m)
WACC = 6.33% (E(820.4m)/V(970.0m) * Re(7.03%) + D(149.6m)/V(970.0m) * Rd(3.18%) * (1-Tc(0.21)))
Discount Rate = 7.03% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 33.63%
[DCF] Fair Price = unknown (Cash Flow -160.3m)
EPS Correlation: -33.84 | EPS CAGR: 0.0% | SUE: 0.34 | # QB: 0
Revenue Correlation: 54.26 | Revenue CAGR: 89.54% | SUE: 4.0 | # QB: 1
EPS next Year (2026-12-31): EPS=-1.46 | Chg7d=+0.000 | Chg30d=+0.221 | Revisions Net=+4 | Growth EPS=+47.6% | Growth Revenue=+278.7%

Additional Sources for KALV Stock

Fund Manager Positions: Dataroma | Stockcircle